Related Experiment Video

Updated: Aug 21, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Targeting gastrin-releasing peptide receptors for cancer treatment

Jiehua Zhou1, Jian Chen, Michael Mokotoff

  • 1Division of Blood and Marrow Transplantation, Department of Medicine and Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA 92093-0960, USA.

Anti-Cancer Drugs
|October 30, 2004
PubMed

Insights

Targeting bombesin/gastrin-releasing peptide receptors (BN/GRP-Rs), which are prevalent in many cancers but scarce in normal tissues, offers a promising strategy for cancer diagnosis and treatment. BN/GRP-R inhibition has shown potential in blocking cancer growth, particularly in small cell lung cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Growth factor receptors are crucial in cancer cell proliferation and progression.
  • Targeting these receptors with antibodies or small molecules is a common cancer treatment strategy.
  • Bombesin/gastrin-releasing peptide receptors (BN/GRP-Rs) are overexpressed in various cancers with limited normal tissue distribution.

Purpose of the Study:

  • To review the distribution of BN/GRP-Rs in normal and malignant tissues.
  • To explore various approaches for targeting BN-GRP-Rs in cancer diagnosis and treatment.
  • To highlight the therapeutic potential of BN/GRP-R inhibition.

Main Methods:

  • Literature review of studies on BN/GRP-R distribution.
  • Analysis of preclinical data on BN/GRP-R inhibition in cancer models.
  • Examination of clinical trial outcomes for BN/GRP-R targeting agents.

Main Results:

  • BN/GRP-Rs are widely distributed in numerous cancer types.
  • BN/GRP-R expression is limited in most normal human tissues.
  • Inhibition of BN/GRP-Rs demonstrated efficacy in blocking small cell lung cancer growth in vitro.
  • Early clinical trials targeting human GRP-R indicated anti-cancer activity.

Conclusions:

  • BN/GRP-Rs represent a viable target for cancer therapy.
  • Targeting BN/GRP-Rs holds promise for both cancer diagnosis and treatment.
  • Further research into BN/GRP-R targeting strategies is warranted.

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...